Ocular Therapeutix reports positive top-line data from Phase III OTX-DP trial

11 March 2015

Biopharma company Ocular Therapeutix (Nasdaq: OCUL) has announced positive top-line data from the first of two Phase III trials evaluating lead candidate OTX-DP (dexamethasone) for ocular inflammation and pain following cataract surgery.

The study of 247 patients met both primary efficacy endpoints, achieving a statistically-significant improvement in the reduction of inflammatory cells and pain. Of the patients treated with OTX-DP, 33.7% showed and absence of inflammatory cells in the anterior chamber of the study eye on day 14 following drug product insertion, compared to 14.6% in placebo, while 76.1% receiving OTX-DP reported absence of pain in the study eye on day 8, compared to 36.1% in placebo.

The company is continuing to analyze the safety findings.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK